



Comparison of Virulence Factors of Different *Candida* Species Isolated from the Oral Cavity of Cancer Patients and Normal Individuals

Mehrnoush Maheronnaghsh ¹, Mahnaz Fatahnia ^{1,2,*}, Parvin Dehghan ³, Ali Zarei Mahmoudabadi ^{1,2} and Mahnaz Kheirkhah ³

¹Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

²Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

³Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

*Corresponding author: Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Postal Code: 61357-15794, Ahvaz, Iran. Tel: +98-9163102952, Email: fatahnia@yahoo.com

Received 2019 March 13; Revised 2019 May 14; Accepted 2019 May 17.

Abstract

Background: *Candida* yeast is a normal flora of the mucous membrane of the oral cavity. Various enzymes secreted by *Candida* species play the role of virulence factors in different *Candida* infections including in cancer patients.

Objectives: This study aimed at comparing phospholipase, proteinase, esterase, and hemolytic activities in different *Candida* species isolated from the oral cavity of cancer patients and normal people.

Methods: This study was conducted on 36 cancer patients and 36 healthy people. MspI restriction enzyme for PCR-RFLP method was used to identify the *Candida* species. The enzymatic activity index (EAI) was measured for each enzyme using the relevant protocols.

Results: *Candida albicans* was the most frequent species with the frequency of 26 (72%) and 31 (81.1%) in cancer patients and healthy people, respectively. In healthy individuals and patients, the mean phospholipase activity of *Candida* isolates was 0.795 and 0.775, proteinase activity was 0.7531 and 0.7558, esterase activity was 0.6142 and 0.7186, and hemolysin activity was 0.6317 and 0.5756, respectively.

Conclusions: The results showed that *C. albicans* was the most frequent *Candida* species isolated from healthy people and patients. Phospholipase, proteinase, and hemolysin activity of *Candida* species was higher in patients than in healthy people and hemolytic activity was significantly higher in patients than in healthy subjects ($P < 0.05$). However, *Candida* species in both groups were positive for esterase activity but the mean activity of this enzyme was significantly higher in the healthy group than in the patient group.

Keywords: *Candida* Species, Hemolysin Factor, Phospholipase, Proteinase, Chemotherapy

1. Background

Oral candidiasis, as one of the most common opportunistic fungal infections, can appear in individuals with immunodeficiency, diabetes, and other predisposing conditions (1). Twelve of 14 species of non-*albicans* *Candida* are recognized as the causes of candidiasis but *Candida albicans* is the most common one (2). The oral cavity, gastrointestinal tract, and other mucous membranes are the hosts of *C. albicans*, with other yeasts growing as the normal flora, leading to hematogenous seeding with yeast cells when the immune system is suppressed. According to epidemiological studies, non-*albicans* *Candida* species including *C. tropicalis*, *C. parapsilosis*, *C. krusei*, and *C. glabrata* have repeatedly emerged as human pathogens (3, 4).

Some *Candida* spp. are the normal flora of the oral cavity in healthy people. Strain *C. albicans* can be switch-

ing between the yeast and the pseudo-hyphal forms enabling it to cause diseases in immunosuppressed people ranging from superficial infection to deep disseminated infection (5, 6). *Candida albicans* has multiple virulence factors including adhesion, invasion, yeast-hyphal transition, biofilm formation, phenotypic switching, and secretion of hydrolytic exoenzymes contributing to its colonization and pathogenicity (7). *Candida albicans* is overgrown by exoenzymes that accelerate the adhesion, penetration, and invasion of host tissue (8, 9). *In vivo* study, the filamentous form of *C. albicans* was used to upregulate secreted aspartyl proteinase (SAP). *In vitro* study, *C. albicans* secreted SAP while culturing on media containing bovine serum albumin protein as the nitrogen source.

Among other extracellular hydrolytic enzymes are phospholipase enzymes that damage phospholipids in the

membrane of epithelial cells resulting in cell damage, lysis, and invasion (10). There are four types of phospholipase enzymes (PLA, PLB, PLC, and PLD) (11). The hemolysin enzyme is secreted by *Candida* species and destroys blood cells and releases iron; thus, the increase of iron and its transfer to *Candida* yeast can cause the growth of the yeast and enhance fungal infection (12). In 2008, Almeida et al. showed that *C. albicans* caused more damage to oral epithelial cells containing high levels of ferritin than to cells with low iron levels (13). *In vitro*, esterase activity is considered as one of the pathogenicity factors of the yeast and can be induced in media containing tween 80.

Phospholipase enzymes are related to cell damage, adhesion, penetration and so, invasion (10). They act by destroying phospholipids in epithelial cells resulting in cell membrane damage and lysis (11). Elemental iron stored in the cell during cell destruction is acquired by *Candida* through the production of hemolysin enzymes and metabolism, growth, and enhancement of infections occur after iron chelation and transport to the fungus (12). *In vivo* study, hemolysis is the capability of *C. albicans* to use hemoglobin in erythrocytes as a source of iron (14). In 2008, Almeida showed that, compared to cells containing low iron levels, *C. albicans* brought greater damage to oral epithelial cells containing an elevated concentration of ferritin (13). By acting on the ester bonds in glycerides, esterase enzymes can hydrolyze triacylglycerol (12). *In vitro*, esterase activity is considered one of the pathogenicity factors of this yeast and can be induced in media containing tween 80 (14).

2. Objectives

The aim of the study was to investigate the activity of enzymes including esterase, phospholipase, proteinase, and hemolysin secreted by *Candida* strains isolated from the oral cavity of cancer patients with oral candidiasis and normal people.

3. Methods

In this study, 72 *Candida* isolates were tested among which, 36 isolates were related to oral candidiasis patients under chemotherapy in a previous study including *C. albicans* (n = 26; 72.2%), *C. glabrata* (n = 5; 13.8%), *C. kefyr* (n = 3; 8.3%), *C. krusei* (n = 1; 2.8%), and *C. stellatoidea* (n = 1; 2.8%) (15). Moreover, 36 isolates of *Candida* sp. were obtained from normal oral flora of healthy people by two sterile swabs. To compare the two groups, the participants were controlled for age and sex.

3.1. Preparation of Suspension of *Candida* Isolated from Healthy People

All specimens were cultured on Sabouraud dextrose agar (SDA, Merck, Germany) and incubated aerobically at 37°C for 24 - 48 hours. The CHROM agar *Candida* medium (CHROMagar HiMedia, Mumbai, India) was used to identify *Candida* isolates. PCR-RFLP using an MspI restriction enzyme on the internal transcribed spacer 1 - 5.8 ribosomal DNA-ITS2 (ITS1-5.8S rDNA-ITS2) rDNA region was used to identify isolates to the species level (16). All the isolates of *Candida* species were subcultured at 30°C for 24 hours in SDA plates; then, a suspension was prepared adjusted at 0.5 McFarland standard (1×10^6 to 5×10^6 cells per mL) at the 530 nm wavelength.

3.2. Detection of Some Virulence Factors

3.2.1. Determination of Phospholipase Activity

The test medium contained 65 g SDA, 58.4 g NaCl, and 5.5 g CaCl₂. All were dissolved in 980 mL of distilled water and the solution was sterilized by autoclaving at 121°C psi for 12 minutes. Egg yolk centrifugation was conducted at 5000 g for 30 minutes. The supernatant was added to the prepared medium at the rate of 2%, mixed, and dispensed in plates. An aliquot (10 µL) of the yeasts suspension was inoculated on the test medium and incubated at 37°C for four days. Next, due to the removal of lipids by *Candida* sp., the phospholipase activity was determined as a clear zone around each colony of *Candida* sp. (17, 18).

3.2.2. Determination of Proteinase Activity

The test medium was composed of 60 mL of a solution containing 0.04 g MgSO₄.7H₂O, 0.5 g K₂HPO₄, 1 g NaCl, 0.2 g yeast extract, 4 g glucose, and 0.5 g BSA (bovine serum albumin) and the pH was adjusted to 4.0. Filtration was used to sterilize the solution, followed by mixing with 140 mL of molten agar. An aliquot (10 µL) of the yeasts suspension was inoculated on the test medium and incubated at 37°C for seven days. The proteinase activity was measured as the diameter of clear zones around the colonies (19, 20). Proteinase activity was determined using the amido black staining solution.

3.2.3. Determination of Esterase Activity

The test medium containing 10 g peptone, 5 g NaCl, 0.1 g CaCl₂, and 15 g agar was prepared by dissolving in 1000 mL distilled water, with pH adjusted to 6.5. It was cooled down to about 50°C after being sterilized by autoclaving at 121°C psi for 15 minutes, followed by adding 5 mL of sterilized Tween 80. An aliquot (10 µL) of the yeasts suspension was incubated at 37°C for five days after being inoculated on the test medium. The precipitation zone around the colonies was used to determine the lipase activity (21, 22).

3.2.4. Determination of Hemolysin Activity

Human blood (7%) and glucose (3%) with a final pH of 5.6 were added and dispensed into sterile Petri dishes when the medium was cooled down to 50 - 55°C. An aliquot (10 µL) of the yeasts suspension was inoculated on the test medium and incubated at 37°C for 48 hours. This medium was used to detect the ability of isolates to produce hemolysin (22).

3.3. Enzymatic Assay

In this study, the relevant protocols were used to determine the *in vitro* proteinase, phospholipase, esterase, and hemolysin activities of the 72 isolates (21, 23, 24). The ratio of the colony diameter to the diameter of the unstained zone was used to measure the proteinase and hemolysin activities in mm (23, 25, 26). The phospholipase and esterase activities were defined as the ratio of the colony diameter to the precipitation zone diameter. The measurement of enzymatic activity was based on the enzymatic activity index (EAI) as stated above (27, 28). The ranges of activity were established according to the EAI index: positive ≤ 0.99 and negative EAI = 1.

3.4. Statistical Analysis

SPSS version 21 software was used for statistical analysis. The EAI levels were compared between *Candida* species by using one-way analysis of variance (ANOVA) and post hoc test (LSD). P values of < 0.05 were considered statistically significant.

4. Results

Candida albicans was the most frequently isolated species in 31 (86%) and 26 (72%) specimens of oral cavities of healthy people and cancer patients, respectively. The other detected *Candida* sp. were *C. glabrata* 3 (8%), and *C. krusei* and *C. tropicalis* 1 (3%).

4.1. Phospholipase Activity

Of the 72 studied isolates, 38 (53%) *C. albicans* isolates had phospholipase activity including 23 (64%) from control subjects and 15 (42%) from patients. The enzyme did not have activity in three *C. glabrata* isolates from control subjects. Of the three isolates of *C. glabrata* and *C. kefyr* isolated from patients, two showed phospholipase enzyme activity (Figure 1A). In the patient group, four isolates had phospholipase enzyme activity. Among *Candida kefyr* isolates from patients, two had phospholipase enzyme activity. The phospholipase enzyme activity was positive in four (80%) *C. glabrata* and two (67%) *C. kefyr* isolates from the patient group (Figure 1A). The mean EAI for phospholipase

was 0.7750 and 0.7950 in the cancer patient and normal groups, respectively (Table 1). According to the results, the average activity of the phospholipase enzyme was more in patients than in control subjects, but did not show a statistically significant difference between the two groups ($P > 0.05$).

4.2. Esterase Activity

The enzyme activity was positive in 31 (86%) *C. albicans* isolates from healthy people and 22 (61%) from patients. Three (8%) *C. glabrata* isolates from control subjects did not show the enzymatic activity. Out of five isolates from patients, three (8%) showed esterase activity. Of three (8%) isolates of *C. kefyr* from patients, 100% showed esterase activity (Figure 1B). The mean EAI for esterase was 0.7186 and 0.6142 in the cancer patient and normal groups, respectively (Table 2). According to the results, the production of esterase enzyme in *Candida* species in the study population could not be the cause of oral candidiasis.

4.3. Hemolysin Activity

The hemolysin enzyme activity was positive in 30 (83%) and 26 (72%) *C. albicans* isolates from the control and patient groups, respectively. Of eight (100%) isolates of *C. glabrata* in both control and case groups, the hemolysin enzyme activity was positive in three (8%) and five (14%) isolates, respectively, showing 100% activity in the two groups. Three (8%) *C. kefyr* isolates from patients showed 100% hemolysin activity (Figure 2A). The mean EAI for hemolysin factor was 0.5756 and 0.6317 in cancer patients and normal groups, respectively (Table 3). According to the results, the hemolysin activity of *Candida* species was significantly higher in the patient group than in the control group ($P < 0.05$).

4.4. Proteinase Activity

Of the 43 *C. albicans* isolates positive for proteinase activity, 26 were related to control subjects and 15 to patients. *Candida glabrata* isolated from the controls showed 100% activity of the proteinase enzyme while three out of five isolates from the patients showed the activity of this enzyme. Of the three *C. kefyr* isolates from the patients, two isolates showed the proteinase activity (Figure 2B). The mean EAI for proteinase was 0.7558 and 0.7531 in cancer patients and normal group, respectively (Table 4). According to the results, the mean activity of the proteinase enzyme was not significantly different between the two groups ($P > 0.05$).

$$\text{Enzymatic activity index} = \frac{\text{Colony diameter}}{\text{Colony diameter} + (\text{clear zone diameter or Sediment diameter})} \quad (1)$$


Table 1. Comparison of Phospholipase Activity in Different *Candida* Species Isolated from Cancer Patients and Normal Individuals^{a,b}

Candida Species	Normal Individuals		Cancer Patients		Total	
	Negative	Positive	Negative	Positive	Negative	Positive
<i>Candida albicans</i>	8 (22)	23 (64)	11 (31)	15 (42)	19 (26)	38 (53)
<i>C. glabrata</i>	3 (8)	0	1 (3)	4 (11)	4 (6)	4 (6)
<i>C. kefyr</i>	0	0	1 (3)	2 (6)	1 (1)	2 (3)
<i>C. krusei</i>	1 (3)	0	0	1 (3)	1 (1)	1 (1)
<i>C. tropicalis</i>	0	1 (3)	0	0	0	1 (1)
<i>C. stellatoidea</i>	0	0	1 (3)	0	1 (1)	0
Total	12 (33)	24 (67)	14 (39)	22 (61)	26 (36)	46 (64)
	36 (100)		36 (100)		72 (100)	
Mean EAI	0.7950		0.7750			

Abbreviation: EAI, enzymatic activity index.

^aValues are expressed as No. (%).

^bP value = 0.48.

**Figure 1.** Sediments (precipitates) around the colony for (A) phospholipase and (B) esterase activity

5. Discussion

Infections caused by *Candida* species are increasing in immunocompromised patients. Oral candidiasis is one of the most common opportunistic infections in this group of patients (29-31). The main cause of candidiasis is *C. albicans* although non-*albicans* such as *C. glabrata* and *C. krusei* are increasing (32). In the present study, among 36 isolates from healthy subjects 31 (86%) *C. albicans* and five (14%) non-*albicans* isolates were identified using pheno-

typic and molecular methods. Therefore, in the control group, similar to patients undergoing chemotherapy, *C. albicans* showed the most identified isolates. *C. albicans* is known as an opportunistic pathogen causing the disease development by attacking the host tissue (8). *Candida albicans* can exist as normal flora in the mouth of all individuals under normal conditions but this yeast can cause disease in the oral cavity in certain conditions, especially when the body resistance is reduced (33).

One of the virulence factors in oral candidiasis is the

Table 2. Comparison of Esterase Activity in Different *Candida* Species Isolated from Cancer Patients and Normal Individuals^{a,b}

Candida Species	Normal Individuals		Cancer Patients		Total	
	Negative	Positive	Negative	Positive	Negative	Positive
<i>Candida albicans</i>	0	31 (86)	4 (11)	22 (61)	4 (6)	53 (74)
<i>C. glabrata</i>	3 (8)	0	2 (6)	3 (8)	5 (7)	3 (4)
<i>C. kefyr</i>	0	0	0	3 (8)	0	3 (4)
<i>C. krusei</i>	0	1 (3)	0	1 (3)	0	2 (3)
<i>C. tropicalis</i>	0	1 (3)	0	0	0	1 (1)
<i>C. stellatoidea</i>	0	0	0	1 (3)	0	1 (1)
Total	3 (8)	33 (92)	6 (17)	30 (83)	9 (13)	63 (87)
Mean EAI	0.6142		0.7186		72 (100)	

Abbreviation: EAI, enzymatic activity index.

^aValues are expressed as No. (%).^bP value = 0.009.**Table 3.** Comparison of Hemolysin Factor Activity in Different *Candida* Species Isolated from Cancer Patients and Normal Individuals

Candida Species	Normal Individuals		Cancer Patients		Total	
	Negative	Positive	Negative	Positive	Negative	Positive
<i>Candida albicans</i>	1 (3)	30 (83)	0	26 (72)	1 (1)	56 (78)
<i>C. glabrata</i>	0	3 (8)	0	5 (14)	0	8 (11)
<i>C. kefyr</i>	0	0	0	3 (8)	0	3 (4)
<i>C. krusei</i>	0	1 (3)	0	1 (3)	0	2 (3)
<i>C. tropicalis</i>	0	1 (3)	0	0	0	1 (1)
<i>C. stellatoidea</i>	0	0	0	1 (3)	0	1 (1)
Total	1 (3)	35 (97)	0	36 (100)	1 (1)	71 (99)
Mean EAI	0.6317		0.5756		72 (100)	

Abbreviation: EAI, enzymatic activity index.

^aValues are expressed as No. (%).^bP value = 0.004.

adhesion of the yeast to the host cell surface. In this regard, various hydrolytic enzymes have been identified in *Candida* sp. such as phospholipase, proteinase, and esterase involved in *Candida* colonization in the host cell (34). In this study, *Candida* isolates from patients with oral candidiasis showed variable enzymatic activities compared to *Candida* isolates from the control group. Thus, almost 100% of *Candida* species possessed phospholipase and proteinase activity and the secretion of these enzymes was higher in the oral candidiasis patients under chemotherapy than in the oral cavity normal flora of healthy subjects although with no statistically significant difference. In a study by Tsang et al. investigating oral candidiasis isolates from diabetic patients compared to a control group, they found that the secretion of these enzymes was positive in both groups with

more secretion in the patient group (21).

In a study by Price et al. examining how these enzymes can act on the host, it was found that by digesting the host cell membrane, these enzymes can cause sustained adhesion of the yeast cell to the host and ultimately lead to infection. They showed that the development of the disease by different strains of *Candida* is dependent on the activity level of the enzyme (24, 35). In our study, the mean hemolytic activity of *Candida* species was significantly higher in chemotherapy patients than in the control group, which was consistent with the studies conducted by Manns et al. (23) and Watanabe et al. (36). They reported that hemolysin enzymes in different strains of *Candida* could cause iron release from red blood cells and the free iron in saliva is necessary for the pathogenicity of var-




Figure 2. Translucent (clear) zone around the colony for (A) hemolysin and (B) proteinase activity

Table 4. Comparison of Proteinase Activity in Different *Candida* Species Isolated from Cancer Patients and Normal Individuals

<i>Candida</i> Species	Normal Individuals		Cancer Patients		Total	
	Negative	Positive	Negative	Positive	Negative	Positive
<i>Candida albicans</i>	5 (14)	26 (72)	9 (25)	17 (47)	14 (19)	43 (60)
<i>C. glabrata</i>	0	3 (8)	2 (6)	3 (8)	2 (3)	6 (8)
<i>C. kefyr</i>	0	0	1 (3)	2 (6)	1 (1)	2 (3)
<i>C. krusei</i>	1 (3)	0	0	1 (3)	1 (1)	1 (1)
<i>C. tropicalis</i>	1 (3)	0	0	0	1 (1)	0
<i>C. stellatoidea</i>	0	0	0	1 (3)	0	1 (1)
Total	7 (19)	29 (81)	12 (33)	24 (67)	19 (26)	53 (74)
	36 (100)		36 (100)		72 (100)	
Mean EAI	0.7531		0.7558			

Abbreviation: EAI, enzymatic activity index.

^aValues are expressed as No. (%).

^bP value = 0.14.

ious strains of candida (13, 23, 36).

In the present study, all *Candida* species in both groups had esterase activity and the mean activity of this enzyme in healthy subjects was significantly higher than that of the patient group. Kumar et al. in a study detected different levels of esterase activity in different *Candida* sp. They found the highest activity of this enzyme in *C. albicans* species (37). Therefore, in the present study, the higher mean total activity of esterase in healthy individuals could be due to the more prevalence of *C. albicans* isolates than their prevalence in the patient group. Recently, Noori et al. in a study on *Candida* species isolated from individuals with vulvovaginal candidiasis showed no sig-

nificant relationship between esterase production and the presence of VVC. Their results are similar to our study findings (38). Most *Candida* species isolated from humans secrete three groups of hydrolytic enzymes including phospholipase, proteinase, and esterase following the mycelial growth, which can facilitate their active penetration into host cells; they can be identified by quantitative and qualitative methods as virulence factors (39, 40).

In this study, *C. albicans* isolates were more prevalent than other *Candida* species in both control and case groups and *C. albicans* species showed the highest secretion of these four enzymes in both groups. A study by Issa et al. found that *C. albicans* species isolated from the oral cav-

ity and other parts of the human body have the potential for more enzymatic secretion than other *Candida* species (41). However, different studies have reported that *Candida* strains isolated from infected areas in patients and healthy people show a significant potential for the secretion of hydrolytic enzymes. Therefore, it can be concluded that all commensal strains are opportunistic and are able to develop the disease in favorable conditions (8, 42).

5.1. Conclusions

The activity of the extracellular *C. albicans* enzymes in both groups was more than the activity of non-*albicans*, explaining the role of these factors in the development of diseases caused by these yeasts, especially *C. albicans*. Phospholipase, proteinase, and hemolysin activity of *Candida* species was higher in patients than in healthy people and hemolytic activity was also significantly higher in patients than in healthy subjects ($P < 0.05$). Esterase activity of *Candida* species was significantly higher in patients than in healthy subjects. How the pathogenesis of *Candida* sp. is working is essential to develop new antifungal agents and determine the cause of drug resistance and management of patients. This study helped us to better understand the mechanism of *Candida* sp. However, more research is needed in this regard.

Acknowledgments

We are thankful to Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, for cooperation in this study.

Footnotes

Authors' Contribution: Mahnaz Fatahnia was involved in the study design and interpretation of the data of the study and final editing of the manuscript. Mehrnoush Maheronnaghsh contributed to all the steps of experimental work, data analysis, and preparation of the manuscript draft. Ali Zarei Mahmoudabadi contributed interpretation of the data. Parvin Dehghan and Mahnaz Kheirkhah contributed for collection and preparation of clinical samples.

Conflict of Interests: The authors do not declare any conflicts of interest.

Ethical Approval: The study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.RC.1396.1094).

Financial Disclosure: There are no financial conflicts of interest to disclose.

Funding/Support: This study was supported by a grant as approved at Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (grant No. 96149).

Patient Consent: It is not declared by the authors.

References

- Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. *Clin Microbiol Rev.* 2000;**13**(4):547-58. doi: [10.1128/cmr.13.4.547-558.2000](https://doi.org/10.1128/cmr.13.4.547-558.2000). [PubMed: [11023956](https://pubmed.ncbi.nlm.nih.gov/11023956/)]. [PubMed Central: [PMC88948](https://pubmed.ncbi.nlm.nih.gov/PMC88948/)].
- Aarstehfar A, Daneshnia F, Kord M, Roudbary M, Zarrinfar H, Fang W, et al. Comparison of 2i-Plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA sequencing for a wide range of clinically isolated yeast species: Improved identification by combining 2i-Plex PCR and API 20C AUX as an alternative strategy for developing countries. *Front Cell Infect Microbiol.* 2019;**9**:21. doi: [10.3389/fcimb.2019.00021](https://doi.org/10.3389/fcimb.2019.00021). [PubMed: [30828570](https://pubmed.ncbi.nlm.nih.gov/30828570/)]. [PubMed Central: [PMC6385604](https://pubmed.ncbi.nlm.nih.gov/PMC6385604/)].
- Jacobsen ID, Wilson D, Wachtler B, Brunke S, Naglik JR, Hube B. *Candida albicans* dimorphism as a therapeutic target. *Expert Rev Anti Infect Ther.* 2012;**10**(1):85-93. doi: [10.1586/eri.11.152](https://doi.org/10.1586/eri.11.152). [PubMed: [22149617](https://pubmed.ncbi.nlm.nih.gov/22149617/)].
- Esmailzadeh A, Zarrinfar H, Fata A, Sen T. High prevalence of candiduria due to non-*albicans* *Candida* species among diabetic patients: A matter of concern? *J Clin Lab Anal.* 2018;**32**(4). e22343. doi: [10.1002/jcla.22343](https://doi.org/10.1002/jcla.22343). [PubMed: [29076587](https://pubmed.ncbi.nlm.nih.gov/29076587/)].
- Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous *C. albicans* mutants are avirulent. *Cell.* 1997;**90**(5):939-49. doi: [10.1016/S0092-8674\(00\)80358-X](https://doi.org/10.1016/S0092-8674(00)80358-X). [PubMed: [9298905](https://pubmed.ncbi.nlm.nih.gov/9298905/)].
- Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in *Candida albicans*. *FEMS Microbiol Lett.* 2002;**214**(1):95-100. doi: [10.1111/j.1574-6968.2002.tb11330.x](https://doi.org/10.1111/j.1574-6968.2002.tb11330.x). [PubMed: [12204378](https://pubmed.ncbi.nlm.nih.gov/12204378/)].
- Mayer FL, Wilson D, Hube B. *Candida albicans* pathogenicity mechanisms. *Virulence.* 2013;**4**(2):119-28. doi: [10.4161/viru.22913](https://doi.org/10.4161/viru.22913). [PubMed: [23302789](https://pubmed.ncbi.nlm.nih.gov/23302789/)]. [PubMed Central: [PMC3654610](https://pubmed.ncbi.nlm.nih.gov/PMC3654610/)].
- Schaller M, Borelli C, Kortling HC, Hube B. Hydrolytic enzymes as virulence factors of *Candida albicans*. *Mycoses.* 2005;**48**(6):365-77. doi: [10.1111/j.1439-0507.2005.01165.x](https://doi.org/10.1111/j.1439-0507.2005.01165.x). [PubMed: [16262871](https://pubmed.ncbi.nlm.nih.gov/16262871/)].
- KD, T, J, A.M. In vitro evaluation of virulence factors of *Candida* species isolated from oral cavity. *J Microbiol Antimicrob.* 2015;**7**(3):28-32. doi: [10.5897/jma2015.0337](https://doi.org/10.5897/jma2015.0337).
- Kabir MA, Hussain MA, Ahmad Z. *Candida albicans*: A model organism for studying fungal pathogens. *ISRN Microbiol.* 2012;**2012**:538694. doi: [10.5402/2012/538694](https://doi.org/10.5402/2012/538694). [PubMed: [23762753](https://pubmed.ncbi.nlm.nih.gov/23762753/)]. [PubMed Central: [PMC3671685](https://pubmed.ncbi.nlm.nih.gov/PMC3671685/)].
- Bhat V, Sharma S, Shetty V, Shastry C, Rao V. Extracellular enzymes of *Candida albicans* and their role in development of denture stomatitis-a review. *JIADS.* 2011;**2**(1):26-30.
- Williams D, Lewis M. Pathogenesis and treatment of oral candidosis. *J Oral Microbiol.* 2011;**3**. doi: [10.3402/jom.v3i0.5771](https://doi.org/10.3402/jom.v3i0.5771). [PubMed: [21547018](https://pubmed.ncbi.nlm.nih.gov/21547018/)]. [PubMed Central: [PMC3087208](https://pubmed.ncbi.nlm.nih.gov/PMC3087208/)].
- Almeida RS, Brunke S, Albrecht A, Thewes S, Laue M, Edwards JE, et al. The hyphal-associated adhesin and invasin Als3 of *Candida albicans* mediates iron acquisition from host ferritin. *PLoS Pathog.* 2008;**4**(11). e1000217. doi: [10.1371/journal.ppat.1000217](https://doi.org/10.1371/journal.ppat.1000217). [PubMed: [19023418](https://pubmed.ncbi.nlm.nih.gov/19023418/)]. [PubMed Central: [PMC2581891](https://pubmed.ncbi.nlm.nih.gov/PMC2581891/)].
- Dominic RM, Shenoy S, Baliga S. *Candida* biofilms in medical devices: evolving trends. *Kathmandu Univ Med J (KUMJ).* 2007;**5**(3):431-6. [PubMed: [18604070](https://pubmed.ncbi.nlm.nih.gov/18604070/)].
- Maheronnaghsh M, Tolouei S, Dehghan P, Chadeganipour M, Yazdi M. Identification of *Candida* species in patients with oral lesion un-

- dergoing chemotherapy along with minimum inhibitory concentration to fluconazole. *Adv Biomed Res.* 2016;**5**:132. doi: [10.4103/2277-9175.187394](https://doi.org/10.4103/2277-9175.187394). [PubMed: [27656601](https://pubmed.ncbi.nlm.nih.gov/27656601/)]. [PubMed Central: [PMC5025917](https://pubmed.ncbi.nlm.nih.gov/PMC5025917/)].
16. Singh A, Singh PK, Kumar A, Chander J, Khanna G, Roy P, et al. Molecular and matrix-assisted laser desorption ionization-time of flight mass spectrometry-based characterization of clinically significant melanized fungi in India. *J Clin Microbiol.* 2017;**55**(4):1090-103. doi: [10.1128/JCM.02413-16](https://doi.org/10.1128/JCM.02413-16). [PubMed: [28100598](https://pubmed.ncbi.nlm.nih.gov/28100598/)]. [PubMed Central: [PMC5377836](https://pubmed.ncbi.nlm.nih.gov/PMC5377836/)].
 17. Samaranyake LP, Raeside JM, MacFarlane TW. Factors affecting the phospholipase activity of *Candida* species in vitro. *Sabouraudia.* 1984;**22**(3):201-7. doi: [10.1080/00362178485380331](https://doi.org/10.1080/00362178485380331). [PubMed: [6379916](https://pubmed.ncbi.nlm.nih.gov/6379916/)].
 18. Aoki T, Moro H, Koshio N, Tamura T, Tanabe Y, Kawai H, et al. [Results of antifungal susceptibility testing of *Candida* species and trends of antifungal use in Niigata university medical and dental hospital]. *Rinsho Byori.* 2010;**58**(7):658-63. Japanese. [PubMed: [20715508](https://pubmed.ncbi.nlm.nih.gov/20715508/)].
 19. D'Eca Junior A, Silva AF, Rosa FC, Monteiro SG, de Maria Silva Figueiredo P, de Andrade Monteiro C. In vitro differential activity of phospholipases and acid proteinases of clinical isolates of *Candida*. *Rev Soc Bras Med Trop.* 2011;**44**(3):334-8. doi: [10.1590/S0037-86822011005000036](https://doi.org/10.1590/S0037-86822011005000036). [PubMed: [21901875](https://pubmed.ncbi.nlm.nih.gov/21901875/)].
 20. Lan D, Hou S, Yang N, Whiteley C, Yang B, Wang Y. Optimal production and biochemical properties of a lipase from *Candida albicans*. *Int J Mol Sci.* 2011;**12**(10):7216-37. doi: [10.3390/ijms12107216](https://doi.org/10.3390/ijms12107216). [PubMed: [22072943](https://pubmed.ncbi.nlm.nih.gov/22072943/)]. [PubMed Central: [PMC3211034](https://pubmed.ncbi.nlm.nih.gov/PMC3211034/)].
 21. Tsang CS, Chu FC, Leung WK, Jin LJ, Samaranyake LP, Siu SC. Phospholipase, proteinase and haemolytic activities of *Candida albicans* isolated from oral cavities of patients with type 2 diabetes mellitus. *J Med Microbiol.* 2007;**56**(Pt 10):1393-8. doi: [10.1099/jmm.0.47303-0](https://doi.org/10.1099/jmm.0.47303-0). [PubMed: [17893179](https://pubmed.ncbi.nlm.nih.gov/17893179/)].
 22. Luo G, Samaranyake LP, Yau JY. *Candida* species exhibit differential in vitro hemolytic activities. *J Clin Microbiol.* 2001;**39**(8):2971-4. doi: [10.1128/JCM.39.8.2971-2974.2001](https://doi.org/10.1128/JCM.39.8.2971-2974.2001). [PubMed: [11474025](https://pubmed.ncbi.nlm.nih.gov/11474025/)]. [PubMed Central: [PMC88272](https://pubmed.ncbi.nlm.nih.gov/PMC88272/)].
 23. Manns JM, Mosser DM, Buckley HR. Production of a hemolytic factor by *Candida albicans*. *Infect Immun.* 1994;**62**(11):5154-6. [PubMed: [7927798](https://pubmed.ncbi.nlm.nih.gov/7927798/)]. [PubMed Central: [PMC303238](https://pubmed.ncbi.nlm.nih.gov/PMC303238/)].
 24. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in *Candida albicans*. *Sabouraudia.* 1982;**20**(1):7-14. doi: [10.1080/00362178285380031](https://doi.org/10.1080/00362178285380031). [PubMed: [7038928](https://pubmed.ncbi.nlm.nih.gov/7038928/)].
 25. Kuriyama T, Williams DW, Lewis MA. In vitro secreted aspartyl proteinase activity of *Candida albicans* isolated from oral diseases and healthy oral cavities. *Oral Microbiol Immunol.* 2003;**18**(6):405-7. doi: [10.1046/j.0902-0055.2002.00100.x](https://doi.org/10.1046/j.0902-0055.2002.00100.x). [PubMed: [14622349](https://pubmed.ncbi.nlm.nih.gov/14622349/)].
 26. Willis AM, Coulter WA, Fulton CR, Hayes JR, Bell PM, Lamey PJ. Oral candidal carriage and infection in insulin-treated diabetic patients. *Diabet Med.* 1999;**16**(8):675-9. doi: [10.1046/j.1464-5491.1999.00134.x](https://doi.org/10.1046/j.1464-5491.1999.00134.x). [PubMed: [10477213](https://pubmed.ncbi.nlm.nih.gov/10477213/)].
 27. Galan-Ladero MA, Blanco MT, Sacristan B, Fernandez-Calderon MC, Perez-Giraldo C, Gomez-Garcia AC. Enzymatic activities of *Candida tropicalis* isolated from hospitalized patients. *Med Mycol.* 2010;**48**(1):207-10. doi: [10.3109/13693780902801242](https://doi.org/10.3109/13693780902801242). [PubMed: [19274599](https://pubmed.ncbi.nlm.nih.gov/19274599/)].
 28. Fatahinia M, Poormohamadi F, Zarei Mahmoudabadi A. Comparative study of esterase and hemolytic activities in clinically important *Candida* species, isolated from oral cavity of diabetic and non-diabetic individuals. *Jundishapur J Microbiol.* 2015;**8**(3). e20893. doi: [10.5812/jjm.20893](https://doi.org/10.5812/jjm.20893). [PubMed: [25861439](https://pubmed.ncbi.nlm.nih.gov/25861439/)]. [PubMed Central: [PMC4386073](https://pubmed.ncbi.nlm.nih.gov/PMC4386073/)].
 29. Venkatesan G, Uppoor A, Naik D, Kadkampally D, Maddi A. Oral *Candida* carriage and morphotype differentiation in chronic periodontitis patients with and without diabetes in the indian sub-continent. *Dent J (Basel).* 2015;**3**(4):123-31. doi: [10.3390/dj3040123](https://doi.org/10.3390/dj3040123). [PubMed: [29567932](https://pubmed.ncbi.nlm.nih.gov/29567932/)]. [PubMed Central: [PMC5851191](https://pubmed.ncbi.nlm.nih.gov/PMC5851191/)].
 30. Mushi MF, Mtemisika CI, Bader O, Bii C, Mirambo MM, Gross U, et al. High oral carriage of non-albicans *Candida* spp. among HIV-infected individuals. *Int J Infect Dis.* 2016;**49**:185-8. doi: [10.1016/j.ijid.2016.07.001](https://doi.org/10.1016/j.ijid.2016.07.001). [PubMed: [27401585](https://pubmed.ncbi.nlm.nih.gov/27401585/)].
 31. Mirmortazavi A, Rajati Haghi H, Fata A, Zarrinfar H, Bagheri H, Mehranfard A. Kinetics of antifungal activity of home-generated ozonated water on *Candida albicans*. *Curr Med Mycol.* 2018;**4**(2):27-31. doi: [10.18502/cmm.4.2.67](https://doi.org/10.18502/cmm.4.2.67). [PubMed: [30324154](https://pubmed.ncbi.nlm.nih.gov/30324154/)]. [PubMed Central: [PMC6181063](https://pubmed.ncbi.nlm.nih.gov/PMC6181063/)].
 32. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in *Candida albicans* and emerging non-albicans *Candida* species. *Front Microbiol.* 2016;**7**:2173. doi: [10.3389/fmicb.2016.02173](https://doi.org/10.3389/fmicb.2016.02173). [PubMed: [28127295](https://pubmed.ncbi.nlm.nih.gov/28127295/)]. [PubMed Central: [PMC5226953](https://pubmed.ncbi.nlm.nih.gov/PMC5226953/)].
 33. Sitheeqe MA, Samaranyake LP. Chronic hyperplastic candidosis/candidiasis (candidal leukoplakia). *Crit Rev Oral Biol Med.* 2003;**14**(4):253-67. doi: [10.1177/154411130301400403](https://doi.org/10.1177/154411130301400403). [PubMed: [12907694](https://pubmed.ncbi.nlm.nih.gov/12907694/)].
 34. Cannon RD, Chaffin WL. Oral colonization by *Candida albicans*. *Crit Rev Oral Biol Med.* 1999;**10**(3):359-83. doi: [10.1177/10454411990100030701](https://doi.org/10.1177/10454411990100030701). [PubMed: [10759414](https://pubmed.ncbi.nlm.nih.gov/10759414/)].
 35. Wu T, Samaranyake LP, Cao BY, Wang J. In-vitro proteinase production by oral *Candida albicans* isolates from individuals with and without HIV infection and its attenuation by antimycotic agents. *J Med Microbiol.* 1996;**44**(4):311-6. doi: [10.1099/00222615-44-4-311](https://doi.org/10.1099/00222615-44-4-311). [PubMed: [8606360](https://pubmed.ncbi.nlm.nih.gov/8606360/)].
 36. Watanabe T, Takano M, Murakami M, Tanaka H, Matsuhisa A, Nakao N, et al. Characterization of a haemolytic factor from *Candida albicans*. *Microbiology.* 1999;**145** (Pt 3):689-94. doi: [10.1099/13500872-145-3-689](https://doi.org/10.1099/13500872-145-3-689). [PubMed: [10217503](https://pubmed.ncbi.nlm.nih.gov/10217503/)].
 37. Kumar CP, Menon T, Sundararajan T, Nalini S, Thirunarayan MA, Rajasekaran S, et al. Esterase activity of *Candida* species isolated from immunocompromised hosts. *Rev Iberoam Micol.* 2006;**23**(2):101-3. doi: [10.1016/S1130-1406\(06\)70023-7](https://doi.org/10.1016/S1130-1406(06)70023-7). [PubMed: [16854187](https://pubmed.ncbi.nlm.nih.gov/16854187/)].
 38. Noori M, Dakhili M, Sepahvand A, Davari N. Evaluation of esterase and hemolysin activities of different *Candida* species isolated from vulvovaginitis cases in Lorestan Province, Iran. *Curr Med Mycol.* 2017;**3**(4):1-5. doi: [10.29252/cmm.3.4.1](https://doi.org/10.29252/cmm.3.4.1). [PubMed: [29707672](https://pubmed.ncbi.nlm.nih.gov/29707672/)]. [PubMed Central: [PMC5917094](https://pubmed.ncbi.nlm.nih.gov/PMC5917094/)].
 39. Ahmad S, Khan Z, Mokaddas E, Khan ZU. Isolation and molecular identification of *Candida dubliniensis* from non-human immunodeficiency virus-infected patients in Kuwait. *J Med Microbiol.* 2004;**53**(Pt 7):633-7. doi: [10.1099/jmm.0.05315-0](https://doi.org/10.1099/jmm.0.05315-0). [PubMed: [15184534](https://pubmed.ncbi.nlm.nih.gov/15184534/)].
 40. Shehabi AA, Nazzal SA, Dajani N. Putative virulence factors of *Candida* species colonizing respiratory tracts of patients. *Microb Ecol Health Dis.* 2009;**16**(4):214-7. doi: [10.1080/08910600410025419](https://doi.org/10.1080/08910600410025419).
 41. Issa SY, Badran EF, Aqel KF, Shehabi AA. Epidemiological characteristics of *Candida* species colonizing oral and rectal sites of Jordanian infants. *BMC Pediatr.* 2011;**11**:79. doi: [10.1186/1471-2431-11-79](https://doi.org/10.1186/1471-2431-11-79). [PubMed: [21902841](https://pubmed.ncbi.nlm.nih.gov/21902841/)]. [PubMed Central: [PMC3182898](https://pubmed.ncbi.nlm.nih.gov/PMC3182898/)].
 42. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. *Clin Microbiol Rev.* 2007;**20**(1):133-63. doi: [10.1128/CMR.00029-06](https://doi.org/10.1128/CMR.00029-06). [PubMed: [17223626](https://pubmed.ncbi.nlm.nih.gov/17223626/)]. [PubMed Central: [PMC1797637](https://pubmed.ncbi.nlm.nih.gov/PMC1797637/)].